← Back to Clinical Trials
Recruiting NCT07338240

NCT07338240 SOFA-2 Score in Turkish ICUs

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07338240
Status Recruiting
Phase
Sponsor Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital
Condition Intensive Care Unit Patients
Study Type OBSERVATIONAL
Enrollment 5,200 participants
Start Date 2026-01-19
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 5,200 participants in total. It began in 2026-01-19 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate how well a new scoring system called the Sequential Organ Failure Assessment-2 (SOFA-2) works in adult intensive care units in Türkiye. SOFA-2 is designed to measure the severity of organ dysfunction in critically ill patients using routinely collected clinical and laboratory data. It is an updated version of the original SOFA score and reflects modern intensive care practices. In this multicenter observational study, adult patients admitted to participating intensive care units will be followed during their ICU stay. SOFA and SOFA-2 scores will be calculated during the first 24 hours of admission, and in patients with longer stays, additional scores will be recorded. No additional tests or treatments will be performed as part of the study. The main goal of the study is to examine the relationship between SOFA-2 scores and intensive care unit mortality. The results are expected to help clinicians better assess disease severity and outcomes in critically ill patients.

Eligibility Criteria

Inclusion Criteria: * Adults aged 18 years or older * Admission to a participating intensive care unit in Türkiye * Intensive care unit stay longer than 24 hours Exclusion Criteria: * Patients younger than 18 years * Pregnant patients * Organ donors * Patients with unknown intensive care unit discharge outcomes

Contact & Investigator

Central Contact

Süleyman Yıldırım, Assoc. Prof.

✉ deu.syldrm@gmail.com

📞 +905057143243

Frequently Asked Questions

Who can join the NCT07338240 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Intensive Care Unit Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07338240 currently recruiting?

Yes, NCT07338240 is actively recruiting participants. Contact the research team at deu.syldrm@gmail.com for enrollment information.

Where is the NCT07338240 trial being conducted?

This trial is being conducted at Izmir, Turkey (Türkiye).

Who is sponsoring the NCT07338240 clinical trial?

NCT07338240 is sponsored by Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital. The trial plans to enroll 5,200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology